{"id":16757,"date":"2022-01-05T20:15:54","date_gmt":"2022-01-05T17:15:54","guid":{"rendered":"https:\/\/zdmaa.com\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/"},"modified":"2022-01-05T21:48:04","modified_gmt":"2022-01-05T18:48:04","slug":"new-leukemia-treatment-marks-shift-in-fighting-cancer","status":"publish","type":"post","link":"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/","title":{"rendered":"L\u00f6semi i\u00e7in yeni tedavi, kansere kar\u015f\u0131 m\u00fccadelede bir de\u011fi\u015fime i\u015faret ediyor"},"content":{"rendered":"

L\u00f6semi i\u00e7in yeni tedavi, kansere kar\u015f\u0131 m\u00fccadelede bir de\u011fi\u015fime i\u015faret ediyor<\/span><\/span><\/span><\/span><\/p>\n

\n

T h\u00fccreleri, v\u00fccudun hastal\u0131klara kar\u015f\u0131 m\u00fccadelesinde g\u00fc\u00e7l\u00fc silahlard\u0131r. <\/span>Bu lenfositler yaln\u0131zca vir\u00fcslere ve parazitlere sald\u0131rmakla kalmaz, ayn\u0131 zamanda tekrar ortaya \u00e7\u0131kmalar\u0131 durumunda belirli tehditleri tan\u0131maya da uyum sa\u011flar. <\/span>Ancak bazen T h\u00fccrelerinin yard\u0131ma ihtiyac\u0131 olur, \u00f6zellikle de konu kanserle m\u00fccadele oldu\u011funda. <\/span>Bu yard\u0131m\u0131n bir k\u0131sm\u0131 imm\u00fcnoterapi – T h\u00fccrelerine kanser h\u00fccrelerini bulmalar\u0131na ve yok etmelerine yard\u0131mc\u0131 olacak ekstra ara\u00e7lar sa\u011flayan ila\u00e7lar \u015feklinde gelir. <\/span>\u00d6rne\u011fin, kontrol noktas\u0131 \u00f6nleyici ila\u00e7lar, T h\u00fccrelerinin kanseri tan\u0131mas\u0131n\u0131 \u00f6nleyen yanl\u0131\u015f sinyalleri engellemek i\u00e7in tasarlanm\u0131\u015ft\u0131r. <\/span>\u015eimdi, ara\u015ft\u0131rmac\u0131lar belirli T h\u00fccrelerini g\u00fc\u00e7lendirmenin yeni bir yolunu ke\u015ffettiler ve onlar\u0131 belirli kanser h\u00fccrelerini tan\u0131mlamalar\u0131na ve onlara sald\u0131rmalar\u0131na izin verecek \u015fekilde tasarlanm\u0131\u015f ek bir genle yeniden tasarlad\u0131lar. <\/span>Bu geli\u015fme \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131 \u00e7\u00fcnk\u00fc v\u00fccudun tedavisi zor kanserlerle sava\u015fmas\u0131na yard\u0131mc\u0131 olacak yeni bir yakla\u015f\u0131m\u0131 temsil ediyor.<\/span><\/span><\/p>\n

ABD G\u0131da ve \u0130la\u00e7 Dairesi (FDA) bunu “tarihi bir \u00f6nlem” olarak nitelendirdi ve bu hafta, T h\u00fccrelerine ona kar\u015f\u0131 ba\u015fka bir silah veren CAR T-h\u00fccresi tedavisi veya gen tedavisi ad\u0131 verilen yeni bir imm\u00fcnoterapi t\u00fcr\u00fcn\u00fc onaylad\u0131\u011f\u0131nda yakla\u015f\u0131m\u0131 onaylad\u0131. . <\/span>25 ya\u015f ve alt\u0131ndaki hastalarda tekrarlayan veya diren\u00e7li akut lenfoblastik l\u00f6semi (ALL). <\/span>Amerika Kanser Tedavi Merkezleri t\u0131p ve bilim \u015fefi Dr. Murray Markman, \u201cBu, s\u0131n\u0131rl\u0131 tedavi se\u00e7enekleri olan hastalar\u0131 tedavi etmek i\u00e7in heyecan verici yeni bir geli\u015fme\u201d diyor. <\/span><\/span>\u00ae<\/span><\/span><\/sup> (CTCA).<\/span><\/span><\/p>\n

T-h\u00fccre \u00f6zelle\u015ftirmesi<\/span><\/span><\/h2>\n

Onaylanm\u0131\u015f tedavi, tisagenlecleucel (Kymriah <\/span><\/span>\u00ae<\/span><\/span><\/sup> ), kimerik antijen resept\u00f6r\u00fc (CAR) T h\u00fccreleri olarak adland\u0131r\u0131lan modifiye edilmi\u015f ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerini kullan\u0131r. <\/span>(\u0130ll\u00fczyon, farkl\u0131 hayvanlar\u0131n ba\u015f\u0131, g\u00f6vdesi ve kuyru\u011fu olan efsanevi bir canavard\u0131r.) Bu h\u00fccreler, aferez ad\u0131 verilen bir i\u015flemle kan dola\u015f\u0131m\u0131ndan al\u0131nan hastan\u0131n kendi T h\u00fccreleri kullan\u0131larak her hastaya \u00f6zelle\u015ftirilir. <\/span>H\u00fccreler daha sonra bir laboratuvara g\u00f6nderilir ve burada T h\u00fccrelerini y\u00fczeylerinde spesifik bir antijen (CD19) bulunan l\u00f6semi B h\u00fccrelerini hedeflemeye y\u00f6nlendiren bir protein i\u00e7eren bir gen ile modifiye edilirler. <\/span>Milyarlarca s\u00fcper \u015farjl\u0131 T h\u00fccresi \u00fcretilir ve daha sonra hastaya geri verilir. <\/span>T\u00fcm s\u00fcre\u00e7 yakla\u015f\u0131k \u00fc\u00e7 hafta s\u00fcrer. <\/span>FDA Komiseri Dr. Scott Gottlieb yapt\u0131\u011f\u0131 a\u00e7\u0131klamada, “Hasta h\u00fccrelerini \u00f6l\u00fcmc\u00fcl bir kansere sald\u0131rmak i\u00e7in yeniden programlama yetene\u011fi ile t\u0131bbi inovasyonda yeni bir s\u0131n\u0131ra giriyoruz.” Dedi.<\/span><\/span><\/p>\n

G\u0131da ve \u0130la\u00e7 \u0130daresi’ne g\u00f6re tisagenlecleucel, sitokin sal\u0131n\u0131m sendromu (CRS), grip benzeri semptomlara, y\u00fcksek ate\u015fe ve\/veya ya\u015fam\u0131 tehdit eden n\u00f6rolojik etkilere ve\/veya veya di\u011fer yan etkiler. <\/span>. <\/span>G\u0131da ve \u0130la\u00e7 Dairesi (FDA), tedaviyi kullanan hastanelerin CRS’yi tan\u0131mak ve y\u00f6netmek i\u00e7in akredite olmas\u0131n\u0131 ve e\u011fitilmesini \u015fart ko\u015far. <\/span>FDA, tisagenlecleucel’in onay\u0131n\u0131n yan\u0131 s\u0131ra, CRS’yi <\/span>tedavi etmek <\/span>i\u00e7in tocilizumab (Actemra <\/span><\/span>\u00ae<\/span><\/span><\/sup> ) <\/span>onay\u0131n\u0131 geni\u015fletti <\/span>ve tocilizumab hemen mevcut olmad\u0131k\u00e7a CAR T-h\u00fccre tedavisinin verilmemesi gerekti\u011fini belirtti. <\/span>Ayr\u0131ca CD19 sa\u011fl\u0131kl\u0131 B h\u00fccrelerinde bulundu\u011fundan, tisagenlecleucel bu h\u00fccreleri de \u00f6ld\u00fcrerek enfeksiyon riskini art\u0131rabilir.<\/span><\/span><\/p>\n

L\u00f6semi i\u00e7in devrim niteli\u011finde tedavi<\/span><\/span><\/h2>\n

Emily Whitehead, PBS serisinde yer alan bir hikayede Philadelphia \u00c7ocuk Hastanesinde tedavi g\u00f6rd\u00fc\u011f\u00fcnde 6 ya\u015f\u0131nda olan ilk CAR T-h\u00fccre tedavisi hastalar\u0131ndan biridir. <\/span><\/span>Kanser: T\u00fcm hastal\u0131klar\u0131n imparatoru<\/span><\/span><\/em> . <\/span>Emily’ye, insan imm\u00fcn yetmezlik vir\u00fcs\u00fcnden (HIV) t\u00fcretilen bir vir\u00fcs taraf\u0131ndan de\u011fi\u015ftirilmi\u015f bir doz CAR T h\u00fccresi verildi\u011finde \u00f6l\u00fcm\u00fcn e\u015fi\u011findeydi. <\/span>Emily \u015fimdi 12 ya\u015f\u0131nda ve aktif hastal\u0131k belirtisi g\u00f6stermiyor. <\/span>Tedavi hakk\u0131nda bir FDA duru\u015fmas\u0131nda ailesiyle birlikte g\u00f6r\u00fcnd\u00fc. <\/span>Emily, kemik ili\u011finin \u00e7ok fazla kusurlu lenfosit \u00fcretti\u011fi bir kanser t\u00fcr\u00fc olan ALL’ye sahipti.<\/span><\/span><\/p>\n

\u00c7o\u011fu durumda ALL, kemoterapi, k\u00f6k h\u00fccre nakli veya hedefe y\u00f6nelik tedavi ile ba\u015far\u0131l\u0131 bir \u015fekilde tedavi edilir. Ancak baz\u0131 durumlarda bu tedaviler yeterli sonu\u00e7 vermemekte ve hastal\u0131k \u00e7ok diren\u00e7li hale gelmektedir. Bir klinik \u00e7al\u0131\u015fmada, n\u00fckseden veya diren\u00e7li B h\u00fccreli 63 hastan\u0131n 52’si (y\u00fczde 82), tisagenlecleucel ile tedaviden sonraki \u00fc\u00e7 ay i\u00e7inde hi\u00e7bir hastal\u0131k belirtisi g\u00f6stermedi. CAR T h\u00fccrelerinin, lenfoma ve di\u011fer l\u00f6semi t\u00fcrleri de dahil olmak \u00fczere di\u011fer kan kanserlerinin yan\u0131 s\u0131ra beyin ve anne kanseri gibi kat\u0131 t\u00fcm\u00f6rl\u00fc kanserler i\u00e7in bir tedavi se\u00e7ene\u011fi olup olmayaca\u011f\u0131n\u0131 belirlemek i\u00e7in d\u00fczinelerce klinik \u00e7al\u0131\u015fma devam etmektedir. Dr. Markman, “Kanser y\u00f6netiminde bu biraz yeni yakla\u015f\u0131m\u0131n rol\u00fcn\u00fc belirlemek i\u00e7in ek ara\u015ft\u0131rma \u00e7al\u0131\u015fmalar\u0131 gerekecek” diyor.<\/span><\/span><\/p>\n

Kan kanserlerinin tan\u0131 ve tedavisine adanm\u0131\u015f kanser bak\u0131m\u0131 alan\u0131 olan hematolojik onkoloji hakk\u0131nda daha fazla bilgi edinin.<\/span><\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

L\u00f6semi i\u00e7in yeni tedavi, kansere kar\u015f\u0131 m\u00fccadelede bir de\u011fi\u015fime i\u015faret ediyor T h\u00fccreleri, v\u00fccudun hastal\u0131klara kar\u015f\u0131 m\u00fccadelesinde g\u00fc\u00e7l\u00fc silahlard\u0131r. Bu lenfositler yaln\u0131zca vir\u00fcslere ve parazitlere sald\u0131rmakla kalmaz, ayn\u0131 zamanda tekrar ortaya \u00e7\u0131kmalar\u0131 durumunda belirli tehditleri tan\u0131maya da uyum sa\u011flar. Ancak bazen T h\u00fccrelerinin yard\u0131ma ihtiyac\u0131 olur, \u00f6zellikle de konu kanserle m\u00fccadele oldu\u011funda. Bu yard\u0131m\u0131n bir …<\/p>\n","protected":false},"author":1,"featured_media":16683,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":["post-16757","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized-tr"],"yoast_head":"\nL\u00f6semi i\u00e7in yeni tedavi, kansere kar\u015f\u0131 m\u00fccadelede bir de\u011fi\u015fime i\u015faret ediyor - zdmaa<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L\u00f6semi i\u00e7in yeni tedavi, kansere kar\u015f\u0131 m\u00fccadelede bir de\u011fi\u015fime i\u015faret ediyor - zdmaa\" \/>\n<meta property=\"og:description\" content=\"L\u00f6semi i\u00e7in yeni tedavi, kansere kar\u015f\u0131 m\u00fccadelede bir de\u011fi\u015fime i\u015faret ediyor T h\u00fccreleri, v\u00fccudun hastal\u0131klara kar\u015f\u0131 m\u00fccadelesinde g\u00fc\u00e7l\u00fc silahlard\u0131r. Bu lenfositler yaln\u0131zca vir\u00fcslere ve parazitlere sald\u0131rmakla kalmaz, ayn\u0131 zamanda tekrar ortaya \u00e7\u0131kmalar\u0131 durumunda belirli tehditleri tan\u0131maya da uyum sa\u011flar. Ancak bazen T h\u00fccrelerinin yard\u0131ma ihtiyac\u0131 olur, \u00f6zellikle de konu kanserle m\u00fccadele oldu\u011funda. Bu yard\u0131m\u0131n bir …\" \/>\n<meta property=\"og:url\" content=\"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"zdmaa\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-05T17:15:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-05T18:48:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/ribbon-symbol-g8f33762c3_640.png\" \/>\n\t<meta property=\"og:image:width\" content=\"533\" \/>\n\t<meta property=\"og:image:height\" content=\"640\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tahmini okuma s\u00fcresi\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 dakika\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/\",\"url\":\"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/\",\"name\":\"L\u00f6semi i\u00e7in yeni tedavi, kansere kar\u015f\u0131 m\u00fccadelede bir de\u011fi\u015fime i\u015faret ediyor - zdmaa\",\"isPartOf\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/ribbon-symbol-g8f33762c3_640.png\",\"datePublished\":\"2022-01-05T17:15:54+00:00\",\"dateModified\":\"2022-01-05T18:48:04+00:00\",\"author\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/8aad4cf5d562d4ca835487f6149853e3\"},\"breadcrumb\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/#primaryimage\",\"url\":\"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/ribbon-symbol-g8f33762c3_640.png\",\"contentUrl\":\"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/ribbon-symbol-g8f33762c3_640.png\",\"width\":533,\"height\":640,\"caption\":\"New Leukemia Treatment Marks Shift In Fighting Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629\",\"item\":\"https:\/\/zdmaa.com\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L\u00f6semi i\u00e7in yeni tedavi, kansere kar\u015f\u0131 m\u00fccadelede bir de\u011fi\u015fime i\u015faret ediyor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#website\",\"url\":\"https:\/\/zdmaa.com\/tr\/ro\/\",\"name\":\"zdmaa\",\"description\":\"zdmaa\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/zdmaa.com\/tr\/ro\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/8aad4cf5d562d4ca835487f6149853e3\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/zdmaa.com\/wp-content\/litespeed\/avatar\/dff6d89ac221c1aaf9366bf5b4cd32de.jpg?ver=1779583752\",\"contentUrl\":\"https:\/\/zdmaa.com\/wp-content\/litespeed\/avatar\/dff6d89ac221c1aaf9366bf5b4cd32de.jpg?ver=1779583752\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/zdmaa.com\"],\"url\":\"https:\/\/zdmaa.com\/tr\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"L\u00f6semi i\u00e7in yeni tedavi, kansere kar\u015f\u0131 m\u00fccadelede bir de\u011fi\u015fime i\u015faret ediyor - zdmaa","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/","og_locale":"tr_TR","og_type":"article","og_title":"L\u00f6semi i\u00e7in yeni tedavi, kansere kar\u015f\u0131 m\u00fccadelede bir de\u011fi\u015fime i\u015faret ediyor - zdmaa","og_description":"L\u00f6semi i\u00e7in yeni tedavi, kansere kar\u015f\u0131 m\u00fccadelede bir de\u011fi\u015fime i\u015faret ediyor T h\u00fccreleri, v\u00fccudun hastal\u0131klara kar\u015f\u0131 m\u00fccadelesinde g\u00fc\u00e7l\u00fc silahlard\u0131r. Bu lenfositler yaln\u0131zca vir\u00fcslere ve parazitlere sald\u0131rmakla kalmaz, ayn\u0131 zamanda tekrar ortaya \u00e7\u0131kmalar\u0131 durumunda belirli tehditleri tan\u0131maya da uyum sa\u011flar. Ancak bazen T h\u00fccrelerinin yard\u0131ma ihtiyac\u0131 olur, \u00f6zellikle de konu kanserle m\u00fccadele oldu\u011funda. Bu yard\u0131m\u0131n bir …","og_url":"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/","og_site_name":"zdmaa","article_published_time":"2022-01-05T17:15:54+00:00","article_modified_time":"2022-01-05T18:48:04+00:00","og_image":[{"width":533,"height":640,"url":"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/ribbon-symbol-g8f33762c3_640.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"admin","Tahmini okuma s\u00fcresi":"4 dakika"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/","url":"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/","name":"L\u00f6semi i\u00e7in yeni tedavi, kansere kar\u015f\u0131 m\u00fccadelede bir de\u011fi\u015fime i\u015faret ediyor - zdmaa","isPartOf":{"@id":"https:\/\/zdmaa.com\/tr\/ro\/#website"},"primaryImageOfPage":{"@id":"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/#primaryimage"},"image":{"@id":"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/ribbon-symbol-g8f33762c3_640.png","datePublished":"2022-01-05T17:15:54+00:00","dateModified":"2022-01-05T18:48:04+00:00","author":{"@id":"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/8aad4cf5d562d4ca835487f6149853e3"},"breadcrumb":{"@id":"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/#primaryimage","url":"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/ribbon-symbol-g8f33762c3_640.png","contentUrl":"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/ribbon-symbol-g8f33762c3_640.png","width":533,"height":640,"caption":"New Leukemia Treatment Marks Shift In Fighting Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/zdmaa.com\/tr\/new-leukemia-treatment-marks-shift-in-fighting-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629","item":"https:\/\/zdmaa.com\/tr\/"},{"@type":"ListItem","position":2,"name":"L\u00f6semi i\u00e7in yeni tedavi, kansere kar\u015f\u0131 m\u00fccadelede bir de\u011fi\u015fime i\u015faret ediyor"}]},{"@type":"WebSite","@id":"https:\/\/zdmaa.com\/tr\/ro\/#website","url":"https:\/\/zdmaa.com\/tr\/ro\/","name":"zdmaa","description":"zdmaa","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/zdmaa.com\/tr\/ro\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/8aad4cf5d562d4ca835487f6149853e3","name":"admin","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/image\/","url":"https:\/\/zdmaa.com\/wp-content\/litespeed\/avatar\/dff6d89ac221c1aaf9366bf5b4cd32de.jpg?ver=1779583752","contentUrl":"https:\/\/zdmaa.com\/wp-content\/litespeed\/avatar\/dff6d89ac221c1aaf9366bf5b4cd32de.jpg?ver=1779583752","caption":"admin"},"sameAs":["https:\/\/zdmaa.com"],"url":"https:\/\/zdmaa.com\/tr\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/posts\/16757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/comments?post=16757"}],"version-history":[{"count":2,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/posts\/16757\/revisions"}],"predecessor-version":[{"id":16780,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/posts\/16757\/revisions\/16780"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/media\/16683"}],"wp:attachment":[{"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/media?parent=16757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/categories?post=16757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/tags?post=16757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}